Results 41 to 50 of about 23,315 (198)

Dosing PPARγ Activation With Light Using Fast Relaxing Photoswitches

Angewandte Chemie International Edition, EarlyView.
To achieve spatiotemporal control over PPARγ activity, we designed the fast‐relaxing photoswitchable agonist 6 that selectively activates PPARγ in its light‐induced Z‐state and relaxes within seconds (t1/2 47 s) to the inactive E‐state. This unique profile allowed light‐dosed receptor activation in in vitro settings, enabling biological studies on ...
Loris Knümann, Alba Rodriguez‐Paniagua, Martin Reynders, Silke Duensing‐Kropp, Oliver Thorn‐Seshold, Vasily Morozov, Julian A. Marschner, Daniel Merk   +7 more
wiley   +1 more source

Pioglitazone Protects Against Renal Ischemia-Reperfusion Injury via the AMP-Activated Protein Kinase-Regulated Autophagy Pathway

Frontiers in Pharmacology, 2018
Renal ischemia-reperfusion injury (IRI) is a major cause of acute renal failure. Our previous studies have shown that pioglitazone, a peroxisome proliferators-activated receptor (PPAR)-γ agonist used in type 2 diabetes, protects against renal IRI ...
Wenlin Chen, Xiaoqing Xi, Shuangyang Zhang, Cong Zou, Renrui Kuang, Zhenfeng Ye, Yawei Huang, Honglin Hu   +7 more
doaj   +1 more source

Pioglitazone

, 2006
europepmc   +2 more sources

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Pioglitazone Enhances Cytosolic Lipolysis, β-oxidation and Autophagy to Ameliorate Hepatic Steatosis

Scientific Reports, 2017
Non-alcoholic fatty liver disease closely contributes to the development of obesity and insulin resistance. Even though pioglitazone has been reported to effectively lessen hepatic steatosis in human studies, its molecular mechanism remains unclear. This
Pi-Jung Hsiao, Hsin-Ying Clair Chiou, He-Jiun Jiang, Mei-Yueh Lee, Tusty-Jiuan Hsieh, Kung-Kai Kuo   +5 more
doaj   +1 more source

Pioglitazone Lowers Serum Retinol Binding Protein 4 by Suppressing its Expression in Adipose Tissue of Obese Rats

Cellular Physiology and Biochemistry, 2015
Background/Aims: Pioglitazone, a peroxisome proliferator-activated receptor γ activator, is clinically used to treat insulin resistance. However, the underlying mechanism of pioglitazone's action remains unclear.
Chaoyu Zhu, Yuanyuan Xiao, Xiaohua Liu, Junfeng Han, Jianmei Zhang, Li Wei, Weiping Jia   +6 more
doaj   +1 more source

Comparative efficacy of GLP‐1 RA, tirzepatide and SGLT‐2 inhibitors in metabolic liver disease: A network meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aim Metabolic liver disease, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis, is a major cause of chronic liver dysfunction worldwide, creating an urgent need for effective treatments. This systematic literature review (SLR) and network meta‐analysis (NMA) systematically reviews and compares the efficacy and safety ...
Andrej Belančić, Christina Antza, Anastasios Poutachidis, Smaro Palaska, Elvira Meni Maria Gkrinia, Andrea Katrin Faour, Yusuf Ziya Sener, Seher Sener, Rehena Sultana   +8 more
wiley   +1 more source

Pioglitazone‐induced alterations of purine metabolism in healthy male subjects

Clinical and Translational Science
Pioglitazone is class of thiazolidinediones that activates peroxisome proliferator‐activated receptors (PPARs) in adipocytes to improve glucose metabolism and insulin sensitivity and has been used as a treatment for type 2 diabetes.
Jihyun Kang, Yufei Li, SeungHwan Lee, Kyung‐Sang Yu, Joo‐Youn Cho   +4 more
doaj   +1 more source

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad, Anshu Arora, Arun Arora, Jeena Vaid, Arif Khan   +4 more
wiley   +1 more source

Effects and Potential Mechanisms of Pioglitazone on Lipid Metabolism in Obese Diabetic KKAy Mice

PPAR Research, 2014
This study aimed to analyze the effects and potential mechanisms of pioglitazone on triglyceride and cholesterol metabolism in obese diabetic KKAy mice. Pioglitazone was orally administered to KKAy mice over 30 days.
Jun Peng, Yi Huan, Qian Jiang, Su-juan Sun, Chun-ming Jia, Zhu-fang Shen   +5 more
doaj   +1 more source